You've chosen Americas as your location.

To clear your location selection and return to IPS Global, click below.

Return to IPS Global

You've chosen Americas as your location.

Thank you for choosing a location. This will help us show you the information that matters the most to you.

Continue Change Selection
IPS participates in Jubilant's Groundbreaking Ceremony

IPS Participates in Jubilant HollisterStier’s Groundbreaking Ceremony for $92 Million Expansion

Nov 18, 2021

Blue Bell, Pennsylvania, November 18, 2021 – IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, congratulates Jubilant HollisterStier LLC, a pharmaceutical contract manufacturer that is part of Jubilant Pharma Limited, on the groundbreaking of their new high-speed filling facility, located in Spokane, Washington.

IPS, the architect and engineer of record, was proud to take part in the groundbreaking ceremony held on November 17, 2021. The company supported Jubilant HollisterStier’s site master planning efforts to expand the Spokane site’s capacity. IPS provided complete design and engineering services for the 50,000 square foot expansion that will house a high-speed filling line and lyophilizers, increasing the facility’s sterile injectable capacity by 50%.

“As the proven leader in designing, building, and validating advanced aseptic processing facilities with barrier technology, IPS couldn’t be prouder to support this project,” said Mark Butler, IPS’ President and Managing Director - Americas. “Being part of this groundbreaking ceremony is very exciting. We are proud to support Jubilant HollisterStier with this expansion to produce excellent quality and compliant products as they consistently have done for nearly 100 years.”

“Based on our trajectory analysis of the sterile injectable market, as well as ongoing conversations with existing partners, there is need to add capacity at our existing facility,” said Amit Arora, President, Jubilant HollisterStier. “The pandemic has fortified our commitment to being ready to quickly support the innovative pharmaceutical partners we work with, whose drugs play an instrumental role in saving the lives of many.”

“Continuous improvements and growth are at the core of our values at Jubilant. That is why we are very pleased to make this investment of US$92Mn approx. in a state-of-the-art filling machine that features the highest degree of quality and compliance to meet current regulatory standards and service our customer’s need even better” stated Pramod Yadav, CEO Jubilant Pharma Limited.

The new filling line will be commercially available by the end of 2024. Jubilant HollisterStier has already begun filling the 200+ new roles created to support this expansion and is actively recruiting at this time.

About IPS

IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, PA-USA, IPS is one of the fastest-growing companies servicing the life sciences industry with over 1,700 professionals in the US, Canada, Brazil, UK, Ireland, Switzerland, Germany, Singapore, China, and India.

About Jubilant HollisterStier LLC

Jubilant HollisterStier LLC, a part of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full-range of support to streamline the manufacturing process, from process qualifications through commercial release.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit:


Choose Your Location

To customize your experience, select an IPS region or country to view specific information based on your location.

  • Americas
  • United States
  • Canada
  • Brazil
  • All Other Countries

You’ve chosen as your location.

Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.


We use cookies to personalize and enhance your experience on our site. Visit our Privacy Policy to learn more.